Thymoglobulin in Calcineurin Inhibitor and Steroid Minimization Protocol
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00706680 |
|
Recruitment Status : Unknown
Verified February 2008 by University Health Network, Toronto.
Recruitment status was: Recruiting
First Posted : June 27, 2008
Last Update Posted : June 27, 2008
|
Sponsor:
University Health Network, Toronto
Collaborators:
Genzyme, a Sanofi Company
Unity Health Toronto
St. Paul's Hospital, Canada
Information provided by:
University Health Network, Toronto
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This study has been designed to test whether using Thymoglobulin with low dose Cyclosporine and early steroid dosage reduction will minimize both kidney rejection and the development of new onset diabetes mellitus after renal transplant.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Diabetes Graft Rejection | Drug: Thymoglobulin | Phase 4 |
All patients will receive methyl prednisone intravenously pre-operatively, as per institutional practice. Thymoglobulin will be initiated prior to completion of the anastomosis, or if not possible, within 24 hours of transplantation in all patients and a total dose of 6-7.5mg/kg will be given over 3-5 doses. Steroids will be initiated post-operatively at 1mg/kg/day for 2 days, then 0.5mg/kg/day for 2 days, then 0.25mg/kg/day for 2 days and then patients will be placed on 5mg daily for the remainder of the study. All patients will receive Mycophenolic acid at a dose of 2gm/day (Cellcept) or 1440mg/day (Myfortic) post-transplantation with dose adjustment as needed. Cyclosporine micro-emulsion will be initiated when renal function is established or no later than day 10 in a dose of 3mg/kg twice daily with adjustment to achieve a C2 target of 600-800 nanograms/ml.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 30 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Prevention |
| Official Title: | The Use of Thymoglobulin in a Calcineurin Inhibitor and Steroid Minimization Protocol |
| Study Start Date : | February 2008 |
| Estimated Primary Completion Date : | February 2009 |
| Estimated Study Completion Date : | June 2009 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: 1
All subjects meeting the entry criteria will be treated with the study immunosuppressive protocol.
|
Drug: Thymoglobulin
methyl prednisone intravenously pre-operatively, as per institutional practice. Thymoglobulin, initiated prior to completion of the anastomosis, or if not possible, within 24 hours of transplantation for a total dose of 6-7.5mg/kg given over 3-5 doses. Steroids initiated post-operatively at 1mg/kg/day for 2 days, then 0.5mg/kg/day for 2 days, then 0.25mg/kg/day for 2 days. Patients will be placed on 5mg daily for the remainder of the study. All patients will receive Mycophenolic acid at a dose of 2gm/day (Cellcept) or 1440mg/day (Myfortic) post-transplantation with dose adjustment as needed. Cyclosporine micro-emulsion will be initiated when renal function is established or no later than day 10 in a dose of 3mg/kg twice daily with adjustment to achieve a C2 target of 600-800 nanograms/ml.
Other Names:
|
Primary Outcome Measures :
- Percentage of patients developing New Onset Diabetes post transplant, as identified by an oral glucose tolerance test [ Time Frame: 6 months post transplant. ]
Secondary Outcome Measures :
- Incidence of acute rejection [ Time Frame: 6 months post transplant ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- De Novo, single Kidney recipient
- At least 1 HLA mismatch
Exclusion Criteria:
- Recipient of multiple organs
- prior transplant recipient
- Subjects who have Diabetes prior to transplant, as indicated by pre-transplant OGTT
- PRA >10%
- Hepatitis B surface antigen positive
- Hepatitis C antibody positive
- HIV positive
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00706680
Contacts
| Contact: Edward Cole | 416-340-4800 ext 4669 | edward.cole@uhn.on.ca | |
| Contact: Bricio Rodriguez | 416-340-4800 ext 5921 | bricio.rodriguez@uhn.on.ca |
Locations
| Canada, British Columbia | |
| St Paul's Hospital | Not yet recruiting |
| Vancouver, British Columbia, Canada, V6Z 2E8 | |
| Contact: John Gill 604-681-7191 | |
| Principal Investigator: John Gill | |
| Sub-Investigator: David Landsberg | |
| Canada, Ontario | |
| St Michael's Hospital | Not yet recruiting |
| Toronto, Ontario, Canada, M5C 2T2 | |
| Contact: Ramesh Prasad (416) 867-3722 Ramesh.Prasad@utoronto.ca | |
| Principal Investigator: Ramesh Prasad | |
| Sub-Investigator: Jeffrey Zaltzman | |
| University health Network | Recruiting |
| Toronto, Ontario, Canada, M5G 2N2 | |
| Contact: Bricio Rodriguez 416-340-4800 ext 5921 bricio.rodriguez@uhn.on.ca | |
| Sub-Investigator: Carl Cardella | |
| Principal Investigator: Edward Cole | |
Sponsors and Collaborators
University Health Network, Toronto
Genzyme, a Sanofi Company
Unity Health Toronto
St. Paul's Hospital, Canada
Investigators
| Study Director: | Edward Cole | University Health Network, Toronto | |
| Principal Investigator: | John Gill | St. Paul's Hospital | |
| Principal Investigator: | Ramesh Prasad | Unity Health Toronto |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Dr. Edward Cole, University Health Network |
| ClinicalTrials.gov Identifier: | NCT00706680 |
| Other Study ID Numbers: |
07-0619-A |
| First Posted: | June 27, 2008 Key Record Dates |
| Last Update Posted: | June 27, 2008 |
| Last Verified: | February 2008 |
Additional relevant MeSH terms:
|
Cyclosporine Mycophenolic Acid Prednisone Methylprednisolone Hemisuccinate Cyclosporins Thymoglobulin Anti-Inflammatory Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Antineoplastic Agents, Hormonal Antineoplastic Agents Enzyme Inhibitors |
Molecular Mechanisms of Pharmacological Action Immunosuppressive Agents Immunologic Factors Antifungal Agents Anti-Infective Agents Dermatologic Agents Antirheumatic Agents Calcineurin Inhibitors Antibiotics, Antineoplastic Antibiotics, Antitubercular Antitubercular Agents Anti-Bacterial Agents Neuroprotective Agents Protective Agents |